NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

代謝障礙治療藥的全球市場(2020年∼2026年)

Metabolic Disorder Therapeutics Market 2020-2026

出版商 Orion Market Research Pvt Ltd 商品編碼 986532
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
代謝障礙治療藥的全球市場(2020年∼2026年) Metabolic Disorder Therapeutics Market 2020-2026
出版日期: 2020年11月11日內容資訊: 英文
簡介

代謝障礙治療藥的的市場規模預計將在預測期內顯示出顯著增長。糖尿病和肥胖症的患病率上升正在推動市場的增長。

這份報告提供代謝障礙治療藥的世界市場調查,提供市場概要,市場成長要素及阻礙因素分析,市場機會,治療·疾病·各地區的市場規模的變化與預測,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢
  • 規則和規則

第3章 競爭情形

  • 企業佔有率分析
  • 重要的策略分析
  • 主要企業分析
    • AbbVie, Inc.
    • Novo Nordisk A/S
    • Sanofi S.A.
    • Boehringer Ingelheim GmbH
    • AstraZeneca plc

第4章 市場決策要素

  • 動機
  • 阻礙因素
  • 市場機會

第5章 市場細分化

  • 不同治療
    • 藥物治療
    • 基因治療
    • 細胞移植
    • 酵素補充療法
    • 其他
  • 各疾病
    • 肥胖
    • 糖尿病
    • 溶小體儲積症
    • 高膽固醇症
    • 其他

第6章 各地區

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 其他地區

第7章 企業簡介

  • AbbVie, Inc.
  • Actelion Pharmaceuticals, Ltd.
  • Agios Pharmaceuticals, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen, Inc.
  • AstraZeneca plc
  • Biocon, Ltd.
  • BioMarin Pharmaceutical, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co.
  • Cipla, Inc.
  • CymaBay Therapeutics, Inc.
  • Dracen Pharmaceuticals, Inc.
  • Eli Lilly and Co.
  • Intra-Cellular Therapies, Inc.
  • Merck KGaA
  • Novo Nordisk A/S
  • Orchard Therapeutics plc
  • Pfizer, Inc.
  • Sanofi S.A.
  • Shire Pharmaceuticals Group plc
  • Sigilon Therapeutics, Inc.
  • Silence Therapeutics
目錄
Product Code: OMR2022827

Global Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report, By Therapy (Drug Therapy, Gene Therapy, Cellular Transplantation, Enzyme Replacement Therapy, and Others), By Disease (Obesity, Diabetes, Lysosomal Storage Disease, Hypercholesterolemia, and Others) and Forecast, 2020-2026

The global metabolic disorder therapeutics market is estimated to witness significant growth during the forecast period. The rising prevalence of diabetes and obesity is contributing to the growth of the market. According to the International Diabetes Federation (IDF), approximately 463 million adults (20-79 years) had diabetes in 2019, which will rise to 700 million by 2045. The type-2 diabetic population is rising in most countries. In 2019, 374 million people were at increased risk of developing type 2 diabetes. Type-2 diabetes is a metabolic disorder which is characterized by pancreatic B-cell dysfunction and insulin resistance due to the unsettled high blood glucose levels (hyperglycemia).

Insulin sensitizing drugs, including thiazolidinediones and metformin, are used for the treatment of any type 2 diabetic patient. In addition, these drugs can also be used in patients suffering from metabolic syndrome. At the starting of the therapy, metformin is normally used and thereafter insulin sensitizers (PPAR-gamma stimulators) including rosiglitazone are also recommended. PPARgamma (peroxisome- proliferator-activated receptor-gamma) is considered as a crucial therapeutic target to treat diabetes which arises from its effects of hypoglycemic in diabetic patients and also plays a critical role in controlling CVD functions.

Geographically, the global metabolic disorder therapeutics market is classified into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America has the largest share in the biopharmaceutical industry, which may lead to potential share in the production and R&D of metabolic disorder treatments in the region. In addition, the region is significantly driven by the rising prevalence of metabolic disorders such as obesity and diabetes. Asia-Pacific is estimated to witness considerable growth during the forecast period owing to the rising awareness regarding health among the population and improving healthcare infrastructure in the region.

Some crucial players in the market include AbbVie Inc., Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, and AstraZeneca plc. Product launches, mergers and acquisitions, and partnerships and collaborations, are certain strategies adopted by the market players to expand market share and gain a competitive advantage. For instance, in March 2020, AstraZeneca plc declared that it would partner with Silence Therapeutics to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for the treatment of CVD, respiratory, renal, and metabolic disorders. This multi-target partnership will use the established small interfering RNA (siRNA) platform of Silence to detect and progress liver-based targets and develop new delivery methods to target other tissues including the heart, kidney, and lung.

Research Methodology

The market study of the global metabolic disorder therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.

Whitepapers, research-papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Metabolic Disorder Therapeutics Market Research and Analysis by Therapy

2. Global Metabolic Disorder Therapeutics Market Research and Analysis by Disease

The Report Covers:

Comprehensive research methodology of the global metabolic disorder therapeutics market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global metabolic disorder therapeutics market.

Insights about market determinants which are stimulating the global metabolic disorder therapeutics market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AbbVie, Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Novo Nordisk A/S
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Sanofi S.A.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Boehringer Ingelheim GmbH
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. AstraZeneca plc
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Metabolic Disorder Therapeutics Market by Therapy
    • 5.1.1. Drug Therapy
    • 5.1.2. Gene Therapy
    • 5.1.3. Cellular Transplantation
    • 5.1.4. Enzyme Replacement Therapy
    • 5.1.5. Others
  • 5.2. Global Metabolic Disorder Therapeutics Market by Disease
    • 5.2.1. Obesity
    • 5.2.2. Diabetes
    • 5.2.3. Lysosomal Storage Disease
    • 5.2.4. Hypercholesterolemia
    • 5.2.5. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie, Inc.
  • 7.2. Actelion Pharmaceuticals, Ltd.
  • 7.3. Agios Pharmaceuticals, Inc.
  • 7.4. Alexion Pharmaceuticals, Inc.
  • 7.5. Amgen, Inc.
  • 7.6. AstraZeneca plc
  • 7.7. Biocon, Ltd.
  • 7.8. BioMarin Pharmaceutical, Inc.
  • 7.9. Boehringer Ingelheim GmbH
  • 7.10. Bristol-Myers Squibb Co.
  • 7.11. Cipla, Inc.
  • 7.12. CymaBay Therapeutics, Inc.
  • 7.13. Dracen Pharmaceuticals, Inc.
  • 7.14. Eli Lilly and Co.
  • 7.15. Intra-Cellular Therapies, Inc.
  • 7.16. Merck KGaA
  • 7.17. Novo Nordisk A/S
  • 7.18. Orchard Therapeutics plc
  • 7.19. Pfizer, Inc.
  • 7.20. Sanofi S.A.
  • 7.21. Shire Pharmaceuticals Group plc
  • 7.22. Sigilon Therapeutics, Inc.
  • 7.23. Silence Therapeutics

LIST OF TABLES

  • 1. GLOBAL METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2019-2026 ($ MILLION)
  • 2. GLOBAL DRUG THERAPY FOR METABOLIC DISORDER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL GENE THERAPY FORMETABOLIC DISORDER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL CELLULAR TRANSPLANTATION FOR METABOLIC DISORDER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL ENZYME REPLACEMENT THERAPY FOR METABOLIC DISORDER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL OTHER METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 8. GLOBAL METABOLIC DISORDER THERAPEUTICS FOR OBESITY MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL METABOLIC DISORDER THERAPEUTICS FOR DIABETES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL METABOLIC DISORDER THERAPEUTICS FOR LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL METABOLIC DISORDER THERAPEUTICS FOR HYPERCHOLESTEROLEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 12. GLOBAL METABOLIC DISORDER THERAPEUTICS FOR OTHER METABOLIC DISORDERSMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 13. GLOBAL METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 14. NORTH AMERICAN METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 15. NORTH AMERICAN METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2019-2026 ($ MILLION)
  • 16. NORTH AMERICAN METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 17. EUROPEAN METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 18. EUROPEAN METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2019-2026 ($ MILLION)
  • 19. EUROPEAN METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 20. ASIA-PACIFIC METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 21. ASIA-PACIFIC METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2019-2026 ($ MILLION)
  • 22. ASIA-PACIFIC METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 23. REST OF THE WORLD METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2019-2026 ($ MILLION)
  • 24. REST OF THE WORLD METABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL METABOLIC DISORDER THERAPEUTICS MARKET SHARE BY THERAPY, 2019 VS 2026 (%)
  • 2. GLOBALMETABOLIC DISORDER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 3. GLOBAL METABOLIC DISORDER THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD METABOLIC DISORDER THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)